Neuphoria Therapeutics NEUP
NASDAQ NEUP
$2.71 +0.02 (+0.74%)
At close: Nov 11, 2026 · 4:00 PM EST

Neuphoria Therapeutics (NEUP) EBIT Margin (2024 - 2025)

Updated

Neuphoria Therapeutics (NEUP) posted EBIT Margin of -1401.09% for FY2026 (year ended Jun 30, 2026), down 1393.87 percentage points from -7.21% in FY2025.

Analysis

Neuphoria Therapeutics (NEUP) EBIT Margin (2024 - 2025) Analysis & Trends

Since FY2020, Neuphoria Therapeutics has reported EBIT Margin for 5 fiscal years.

  • Annual EBIT Margin shows a four-year change of +6908.54 percentage points (FY2022 to FY2026).
  • The FY2026 figure stands as the lowest annual EBIT Margin since FY2023.
  • Business Quant data shows NEUP's EBIT Margin at -7.21% in FY2025, -145255.68% in FY2023 (-136946.05 pp) and -8309.63% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Neuphoria Therapeutics 335.34 Mn 260.15 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 79.85%
Dec 31, 2024 -558.84%
API Access

Neuphoria Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=NEUP&period=max&api_key=YOUR_API_KEY